TABLE 1.

Results of opsonophagocytic killing assays with human PMNs, type 8 pneumococci, human complement sources, and human IgM and IgA MAbs to type 8 PS

Conditiona	CFUb
	Expt 1	Expt 2	Expt 3
P/PMN/no complement/no MAb	440 ± 120	1,300 ± 200	1,300 ± 400
P/PMN/no complement/D11	390 ± 60	1,100 ± 230	1,100 ± 110
P/PMN/no complement/IgM	440 ± 34	1,300 ± 320	1,200 ± 460
P/PMN/FB−/no MAb	600 ± 140	1,500 ± 320	760 ± 51
P/PMN/FB−/D11	340 ± 89	1,100 ± 110	720 ± 270
P/PMN/FB−/IgM	410 ± 59	1,100 ± 250	710 ± 220
P/PMN/C2−/no MAb	600 ± 120	1,300 ± 220	910 ± 200
P/PMN/C2−/D11	440 ± 100*	1,100 ± 99	610 ± 170
P/PMN/C2−/IgM	690 ± 63	1,300 ± 130	780 ± 210
P/PMN/HS/no MAb	430 ± 71	750 ± 180	1,100 ± 240
P/PMN/HS/D11	120 ± 50*	510 ± 190	550 ± 250
P/PMN/HS/IgM	430 ± 81	770 ± 250	890 ± 220
P/PMN/no complement/no MAb	440 ± 120	1,300 ± 200	1,300 ± 400
P/PMN/no complement/NAD	340 ± 80	1,400 ± 140	1,100 ± 270
P/PMN/no complement/IgA	490 ± 120	1,300 ± 240	1,000 ± 240
P/PMN/FB−/no MAb	600 ± 140	1,500 ± 320	760 ± 51
P/PMN/FB−/NAD	450 ± 150	1,000 ± 250	590 ± 150
P/PMN/FB−/IgA	650 ± 120	1,100 ± 270	620 ± 130
P/PMN/C2−/no MAb	600 ± 120	1,300 ± 220	910 ± 200
P/PMN/C2−/NAD	430 ± 100*	1,300 ± 310	810 ± 120
P/PMN/C2−/IgA	730 ± 92	1,500 ± 240	930 ± 290
P/PMN/HS/no MAb	430 ± 71	750 ± 180	1,100 ± 240
P/PMN/HS/NAD	240 ± 90	750 ± 220*	1,000 ± 140
P/PMN/HS/IgA	360 ± 89	1,100 ± 230	1,200 ± 300

^aP, type 8 pneumococci; PMN, human PMNs; FB⁻, factor B-deficient serum; C2⁻, C2-deficient serum; HS, human serum.

^bCFU of type 8 pneumococci; values represent mean ± standard deviation of duplicate samples for each condition. *, P < 0.05, comparing type-specific MAb to isotype control MAbs using one-way ANOVA and Bonferroni multiple comparison test.